Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Morehead City, NC
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Morehead City, NC
Click here to add this to my saved trials
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Magnolia, TX
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Magnolia, TX
Click here to add this to my saved trials
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Aschaffenburg,
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Aschaffenburg,
Click here to add this to my saved trials
Texting for Diabetes
Adherence to a Diabetes Care Regimen Following Text Message Intervention in Pregnant Women With Diabetes
Status: Enrolling
Updated:  12/31/1969
St. Mary's Health Center
mi
from
Saint Louis, MO
Texting for Diabetes
Adherence to a Diabetes Care Regimen Following Text Message Intervention in Pregnant Women With Diabetes
Status: Enrolling
Updated: 12/31/1969
St. Mary's Health Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Red Raspberry Polyphenols on Gut Microbiome
The Reciprocal Interactions Between Red Raspberry Polyphenols and Gut Microbiome Composition Affect Insulin Sensitivity
Status: Enrolling
Updated:  12/31/1969
Clinical Nutrition Research Center
mi
from
Chicago, IL
Red Raspberry Polyphenols on Gut Microbiome
The Reciprocal Interactions Between Red Raspberry Polyphenols and Gut Microbiome Composition Affect Insulin Sensitivity
Status: Enrolling
Updated: 12/31/1969
Clinical Nutrition Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscaloosa, AL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Concord, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Concord, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Encino, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Encino, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Escondido, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Escondido, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Fresno, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Inglewood, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Inglewood, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Mission Viejo, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Poway, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
San Mateo, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
San Mateo, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Santa Barbara, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tustin, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tustin, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Vista, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Colorado Springs, CO
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
New Britain, CT
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
New Britain, CT
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Norwalk, CT
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Waterbury, CT
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Boca Raton, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hollywood, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Lake Mary, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Lake Mary, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Melbourne, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Merritt Island, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Merritt Island, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Miami, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
West Palm Beach, FL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Athens, GA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Athens, GA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Savannah, GA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Honolulu, HI
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Idaho Falls, ID
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Peoria, IL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Peoria, IL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Springfield, IL
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Lafayette, IN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
New Albany, IN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
New Albany, IN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Des Moines, IA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Des Moines, IA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Shawnee Mission, KA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Topeka, KA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Lexington, KY
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Baton Rouge, LA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Scarborough, ME
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Scarborough, ME
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hyattsville, MD
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hyattsville, MD
Click here to add this to my saved trials